Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism

References

• Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004;89:453–462.
   PubMed Web of Science ®Google Scholar
• Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434–2438.
   PubMed Web of Science ®Google Scholar
• Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf). 2000;52:595–600.
   PubMed Web of Science ®Google Scholar
• Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major unrecognised cardiovascular risk factor in women. Rev Cardiovasc Med 2009;10:83–90.
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–47.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM Sponsored Consensus Workshop Group 2004. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. Ferti Steril 2004;81:19–25.
   Google Scholar
• Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 2006;91:781–785.
   PubMed Web of Science ®Google Scholar
• Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab 2006;91:786–789.
   PubMed Web of Science ®Google Scholar
• Rachoń D, Teede H. Ovarian function and obesity-Interrelationship, impact on women's reproductive lifespan and treatment options. Mol Cell Endocrinol. 2010 Mar 25; 316(2):172–9.
   Google Scholar
• Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. Geneva, World Health Organization, 2000 (WHO Technical Report Series, No. 894; http://libdoc.who.int/trs/WHO_TRS_894.pdf, accessed November 7, 2009).
   Google Scholar
• Balasch J, Fábregues F, Peñarrubia J, Carmona F, Casamitjana R, Creus M, Manau D, Casals G, Vanrell JA. Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH. Hum Reprod 2006;21(7):1884–1893.
   PubMedGoogle Scholar
• Ly LP, Handelsman DJ. Empirical estimation of free testosterone from testosterone and sex hormone-binding globulin immunoassays. Eur J Endocrinol 2005;152(3):471–478.
   PubMedGoogle Scholar
• Moreno-Arias G, Castelo-Branco C, Ferrando J. Paradoxical effect after IPL photoepilation. Dermatol Surg 2002;28:1013–1016.
   PubMed Web of Science ®Google Scholar
• Vidal J, Morinigo R, Codoceo VH, Casamitjana R, Pellitero S, Gomis R. The importance of diagnostic criteria in the association between the metabolic syndrome and cardiovascular disease in obese subjects. Int J Obes 2005;29:668–674.
   Google Scholar
• Kauffman RP, Baker TE, Baker VM, DiMarino P, Castracane VD. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. Am J Obstet Gynecol 2008;198:670 e1–670 e10.
   PubMed Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome, Am J Med 2001;111:607–613.
   PubMed Web of Science ®Google Scholar
• Valkenburg O, Steegers-Theunissen RPM, Smedts HPM, Dallinga-Thie GM, Fauser BCJM, Westerveld EH, Laven JS. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 2008;93:470–476.
   PubMed Web of Science ®Google Scholar
• Legro RS, Azziz R, Ehrmann D, Fereshetian AG, O'Keefe M, Ghazzi MN. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab 2003;88:5137–5144.
   PubMed Web of Science ®Google Scholar
• Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol 1992;37:119–125.
   PubMed Web of Science ®Google Scholar
• Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595–1607.
   PubMed Web of Science ®Google Scholar
• Westerveld HE, Hoogendoorn M, de Jong AWF, Goverde AJ, Fauser BCJM, Dallinga-Thie GM. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutics insights. Pharmacol Ther 2008;119:223–241.
   PubMed Web of Science ®Google Scholar
• Maffei L, Murata Y, Rochira V, Tubert G, Aranda C, Vazquez M, Clyne CD, Davis S, Simpson ER, Carani C. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 2004;89:61–70.
   PubMed Web of Science ®Google Scholar
• Economou F, Xyrafis X, Livadas S, Androulakis II, Argyrakopoulou G, Christakou CD, Kandaraki E, Palioura E, Diamanti-Kandarakis E. In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones (Athens) 2009;8(3):199–206.
   PubMedGoogle Scholar
• Nestler JE, Barlascini CO, Matt DW, Steingold KA, Plymate SR, Clore JN, Blackard WG. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1989;68:1027–1032.
   PubMed Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998;83:2001–2005.
   PubMed Web of Science ®Google Scholar
• Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72:83–89.
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Perini D, Lazzarini V, Parrini D, Genazzani AR. Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels. Fert Steril 2009;92:626–634.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB, Spinas GA, Carmina E. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod 2009;24(9):2286–2292.
   PubMedGoogle Scholar